Haemonetics adds Martin Madaus to its board of directors

Haemonetics Corporation (NYSE: HAE) announced that Martin Madaus has been elected to its board of directors, effective July 24, 2026, according to a company statement.

Dr. Madaus has more than 30 years of experience in the diagnostics and life sciences tools industries. He currently serves as Senior Operating Executive at The Carlyle Group, a role he has held since 2019, advising on healthcare investments and portfolio company performance.

Dr. Madaus previously served as Chairman and Chief Executive Officer of Ortho Clinical Diagnostics, Inc., now known as QuidelOrtho Corporation, where he led the company's business turnaround following its carve-out from Johnson & Johnson. He also served as Chairman, President and Chief Executive Officer of Millipore Corporation, which was acquired by Merck KGaA in 2010, and as President and Chief Executive Officer of Roche Diagnostics North America.

Dr. Madaus currently chairs the board of Repligen Corporation and serves as a board member of Azenta, Inc. He holds a Doctor of Veterinary Medicine from the University of Munich and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover, both in Germany.

Ellen Zane, Chair of Haemonetics' board, said: "His track record of leading complex global organizations, driving operational excellence and creating shareholder value will be invaluable as Haemonetics continues to execute its strategy."

You May Also Be Interested In

• Eldorado Gold names new board chair and lead independent director
• Anne Sweeney resigns from Netflix board of directors
• MGM Resorts CEO Bill Hornbuckle joins Vail Resorts board